US considers rules preserving most pharma licensing deals with China
Sources say the US is working on rules for pharmaceutical investment in China that would likely preserve companies’ ability to strike most licensing deals for Chinese drugs.
The US is working on rules for pharmaceutical companies investing in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according to three people who have been briefed on the process. That would mark a departure from the Trump administration approach.